A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NLME / nonlinear mixed-effects

[Related PubMed/MEDLINE]
Total Number of Papers: 73
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NLME  (>> Co-occurring Abbreviation)
Long Form:   nonlinear mixed-effects
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2022 Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. OFV, PopPK
2  2022 Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients. CFB, COPD, E-RS, IRT, MMRM
3  2022 Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms. PKs, PopPK
4  2021 A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy. CL, IgG, PID, PopPK
5  2021 Multiparameter one-sided tests for nonlinear mixed effects models with censored responses. ---
6  2021 Needle-free iontophoresis-driven beta-adrenergic sweat rate test. ---
7  2021 Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration. NGF, PK, s.c
8  2021 Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies. aHR, Cox-PH, SARS-CoV-2
9  2021 Use of Mixture Dosing and Nonlinear Mixed Effect Modeling of Eight Environmental Contaminants in Rabbits to Improve Extrapolation Value of Toxicokinetic Data. BPS, HCB, MRT, PFOA, PFOS, TD, TK
10  2021 Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody. HA, TG
11  2020 A novel quantification of information for longitudinal data analyzed by mixed-effects modeling. RI
12  2020 Dynamic growth models for Caragana korshinskii shrub biomass in China. BIC, LR, NLFE, NLS
13  2020 Evaluation of non-linear-mixed-effect modeling to reduce the sample sizes of pediatric trials in type 2 diabetes mellitus. LOCF, MMRM
14  2020 Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. MIPD, PK
15  2020 Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children. CL, HSCT, IOV, TDM, Vd
16  2020 Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats. i.v, PK, SAEM, VSS
17  2020 Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets. FM, IM, NCA, PK, TD, UPLC-MS
18  2020 What "Impact" Do NLME Publications Have Outside Our Community? ---
19  2019 A generalized Bayesian nonlinear mixed-effects regression model for zero-inflated longitudinal count data in tuberculosis trials. CFU, TB
20  2019 In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs. NCA, PK
21  2019 Intratumoral distribution of YSNSG cyclopeptide in a mouse melanoma model using microdialysis. ---
22  2019 Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. LASSO, mCRC, OS, PFS
23  2019 Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines. CCLE, CCLs, GDSC
24  2019 Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs. CEF, DCA, I.V, PK, s.c
25  2019 Scoring reading parameters: An inter-rater reliability study using the MNREAD chart. CPS, ICC, MRS, SDev
26  2018 A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat. CMS, MDR-GNB, WB-PBPK
27  2018 Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics. EKF, FOCE, SDEs
28  2018 Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. DRCs, HTS
29  2018 Nonlinear Mixed-Effects Models for PET Data. ---
30  2018 Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. HPLC
31  2018 Robust Bayesian nonlinear mixed-effects modeling of time to positivity in tuberculosis trials. CFU, EBA, TB, TTP
32  2018 Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. ---
33  2017 Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). CF, COX-2, PK
34  2017 Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data. ANPE, AUC, NCA, NPE
35  2017 Joint model-based clustering of nonlinear longitudinal trajectories and associated time-to-event data analysis, linked by latent class membership: with application to AIDS clinical studies. ---
36  2017 Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. ---
37  2017 Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ICP-MS, LiCl, SEA
38  2017 PharmML in Action: an Interoperable Language for Modeling and Simulation. ---
39  2016 A Note on Recurring Misconceptions When Fitting Nonlinear Mixed Models. FO, GHQ, PA, SS
40  2016 Bayesian quantile regression for nonlinear mixed-effects joint models for longitudinal data in the presence of mismeasured covariate errors. MR, QR
41  2016 Formation of parametric images using mixed-effects models: a feasibility study. IVIM, NLLS
42  2016 Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. PKs
43  2016 Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. PK-PD
44  2015 A mixture of hierarchical joint models for longitudinal data with heterogeneity, non-normality, missingness, and covariate measurement error. ---
45  2015 A Nonlinear Mixed Effects Approach for Modeling the Cell-To-Cell Variability of Mig1 Dynamics in Yeast. STS
46  2015 Stochastic nonlinear mixed effects: a metformin case study. PK, SDE
47  2015 Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood. FOCE
48  2014 A Bayesian Nonlinear Mixed-Effects Regression Model for the Characterization of Early Bactericidal Activity of Tuberculosis Drugs. CFU, EBA, TB
49  2014 Bayesian analysis of nonlinear mixed-effects mixture models for longitudinal data with heterogeneity and skewness. ---
50  2014 Nonlinear mixed-effects (NLME) diameter growth models for individual China-Fir (Cunninghamia lanceolata) trees in Southeast China. CS
51  2013 Fitting correlated residual error structures in nonlinear mixed-effects models using SAS PROC NLMIXED. ---
52  2013 How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in rats. CIT, NCA
53  2013 Nonlinear, multilevel mixed-effects approach for modeling longitudinal standard automated perimetry data in glaucoma. dB, LME, OLSLR, VF
54  2013 Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data. PBPK, PK, PPBPK
55  2012 Mixed-effects joint models with skew-normal distribution for HIV dynamic response with missing and mismeasured time-varying covariate. ---
56  2012 Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography. BBB, P-gp, PET, SE
57  2012 Regional characterization of longitudinal DT-MRI to study white matter maturation of the early developing brain. DT-MRI, FA, MD
58  2012 Simultaneous Bayesian inference for skew-normal semiparametric nonlinear mixed-effects models with covariate measurement errors. ---
59  2012 Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations. LME
60  2011 Investigations of a compartmental model for leucine kinetics using non-linear mixed effects models with ordinary and stochastic differential equations. ---
61  2011 Simultaneous Bayesian inference for linear, nonlinear and semiparametric mixed-effects models with skew-normality and measurement errors in covariates. LME, SNLME
62  2010 A bayesian approach to joint mixed-effects models with a skew-normal distribution and measurement errors in covariates. ---
63  2010 In vitro determination of the chromatic effect of a silver nanoparticles solution linked to the gantrez S-97 copolymer on tooth enamel. NNPs
64  2010 Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. ANOVA, FP, HTG, SNP
65  2010 Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies. ---
66  2009 Population pharmacokinetic and pharmacodynamic analysis in allergic diseases. ---
67  2009 Review: efficient rehabilitation trial designs using disease progress modeling: a pediatric traumatic brain injury example. RCTs, TBI
68  2008 A nonlinear mixed-effect mixture model for functional mapping of dynamic traits. QTL
69  2008 Nonlinear mixed-effects modeling of MNREAD data. AMD
70  2008 Statistical model to evaluate in vivo activities of antimalarial drugs in a Plasmodium cynomolgi-macaque model for Plasmodium vivax malaria. ---
71  2007 Simultaneous inference for semiparametric nonlinear mixed-effects models with covariate measurement errors and missing responses. ---
72  2005 Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. ---
73  2002 The study of long-term HIV dynamics using semi-parametric non-linear mixed-effects models. ---